Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 6Genitourinary 2CNS 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Neuroblastoma 44Ganglioneuroblastoma 6Brain Neoplasms 6Sarcoma 5Neoplasms 5Glioma 5Glioblastoma 5Central Nervous System Neoplasms 3Astrocytoma 3Optic Nerve Glioma 2Oligodendroglioma 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Breast Neoplasms 2Bone Neoplasms 2Wilms Tumor 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neurofibromatosis 1 1

Interventions

Irinotecan 3Temozolomide 2Doxorubicin 2Cyclophosphamide 2robatumumab 1palbociclib 1liposomal doxorubicin 1cc-486 1Vincristine 1Topotecan 1Taxes 1Surveys and Questionnaires 1Quality of Life 1Psychology, Positive 1Patient Reported Outcome Measures 1Paclitaxel 1Observation 1Molecular Diagnostic Techniques 1Methods 1Lomustine 1Injections 1Immunotherapy 1Ifosfamide 1Genetic Testing 1Gemcitabine 1Etoposide 1Drug Therapy 1Cyproheptadine 1Carboplatin 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bone Neoplasms × Doxorubicin × CNS × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Merck Sharp & Dohme LLC

Phase 1 Terminated
4 enrolled 8 charts
CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡